Is Craig Venter, the so called “bad boy of biology”, about to announce the world’s first synthetic lifeform? (or ‘Syn’ for short)… we don’t know. According to New Scientist “rumours are circulating that his institute will soon unveil the first synthetic bacterium”. What we do know is that he has applied for a patent with broad claims that include a synthetic organism itself…
As well as dealing with Monsanto in Munich this week, ETC Group has also been raising the alarm about a massive geo-engineering experiment scheduled for this month around Galapagos by Planktos Inc. Here is an open reply to a public attack on our press release.
On October 10, ETC Group attended the US Food and Drug Administration’s first public meeting on nanotechnology. About 40 people had signed up to make presentations, and we were each given eight minutes to say our piece to the FDA’s newly-formed Nanotechnology Task Force. (You can read the text of ETC Group’s presentation here.)
It [...]
Nano-Drug’s Dirty Little Secret
ETC Group’s September 2006 report on nanomedicine, Nanotech Rx, requires some updating. After all, it’s nearly 30 days old. Our report mentions the nano-drug Abraxane, and it acknowledges that approval of the cancer drug was a watershed event for the nanotech industry. But important details are emerging. On October 1 the [...]
The Economist this week has a Special Report on Synthetic Biology , the new field of building artificial life forms from scratch. As is to be expected from the Economist, this is a fairly upbeat assesment of the technology that fails to mention the growing opposition to Synthetic Biology, signalled a few months ago when almost forty civil society groups, trade unions and scientific associations signed an open letter calling for caution.
Here at ETC we have been busy writing our own special report on Synthetic Biology (which we are calling ‘Extreme Genetic Engineering’ -
Silvia Ribeiro*
The biotech company Ventria Biosciences sponsored tests, on babies and children hospitalized at two pediatric institutes in Peru, of two new experimental drugs derived from transgenic rice that was genetically engineered with synthetic human genes to produce artificial human milk proteins.
The experiments - results of which were revealed this May in the US [...]
While some ETC Group staff were in Caracas strategizing with partners to strengthen the global opposition to Terminator, others of us were subjected to the slog of the CBD meeting in Granada. And one of us was spending a few days with unlimited access to free chocolate at Swiss Re’s opulent Centre for Global Dialogue near Zurich. Swiss Re, the world’s largest re-insurer (an insurer of insurance companies) is concerned - no surprise - about those risks associated with nanotechnology that may result in financial losses for the company.
Not content with heading for the stars, the corporate sponsored X-Foundation that awards the X-prize has now set a bounty for commericalising the neXt frontier - the human genome. According to this article in the Wall Street Journal the X-foundation will award a new X-prize of between $5-$20 million to the first inventor of a gene sequencer that can decode the DNA of 100 people in a matter of weeks. behind it is craig venter, the genomics mogul.
(et cet er a) and other things; such as human rights, biodiversity, biopiracy, converging technologies, global governance and corporate concentration. An experimental growing plot for news, views and new ideas.
